BofA raised the firm’s price target on Argenx (ARGX) to $1,006 from $942 and keeps a Buy rating on the shares. Argenx remains one of the analyst’s top picks for 2026 as the firm thinks focus will remain on the commercial launch of Vyvgart in gMG and CIDP, but it sees opportunities for upside from “myriad data catalysts in 2026.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,160 from $1,085 at Guggenheim
- Argenx downgraded to Neutral from Outperform at Baird
- argenx: Strong Growth and Pipeline Potential Already Priced In, Warranting a Neutral/Hold Rating
- Argenx Moves Ahead With Its Phase 2 Study on ARGX-119 for Pediatric SMA
- Argenx price target raised to $925 from $860 at RBC Capital